Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers

Frontiers in Bioscience

Volumn 18, Issue 2, 2013, Pages 520-542

  Box, Carol ^a   Zimmermann, Miriam ^a   Eccles, Suzanne ^a,b  

^a McElwain Laboratories   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Antibody; Epidermal Growth Factor Receptor; Head and Neck; Inhibitor; Receptor Tyrosine Kinase; Resistance; Response; Review; Squamous Cell Carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; MONOCLONAL ANTIBODY; PANITUMUMAB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TUMOR MARKER; VASCULOTROPIN RECEPTOR;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG RESISTANCE; HEAD AND NECK TUMOR; HUMAN; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84878861605     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4118     Document Type: Article

References (214)

1. J Ferlay, HR Shin, F Bray, D Forman, C Mathers, DM Parkin: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127(12), 2893-917 (2010)
2. ME Prince, LE Ailles: Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol, 26(17), 2871-5 (2008)
3. A Argiris, MV Karamouzis, D Raben, RL Ferris: Head and neck cancer. Lancet, 371(9625), 1695-709 (2008) (Pubitemid 351671886)
4. EM Smith, LM Rubenstein, TH Haugen, M Pawlita, LP Turek: Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol, 2012, 571862 (2012)
5. KK Ang, EM Sturgis: Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol, 22(2), 128-42 (2012)
6. CS Kong, B Narasimhan, H Cao, S Kwok, JP Erickson, A Koong, N Pourmand, QT Le: The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys, 74(2), 553-61 (2009)
7. C Box, SJ Rogers, M Mendiola, SA Eccles: Tumourmicroenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol, 20(3), 128- 38 (2010)
8. M Allen, JL Jones: Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol, 223(2), 162-76 (2011)
9. S Patiar, AL Harris: Role of hypoxia-inducible factor- 1alpha as a cancer therapy target. Endocr Relat Cancer, 13 Suppl 1, S61-75 (2006) (Pubitemid 46219249)
10. DM Aebersold, P Burri, KT Beer, J Laissue, V Djonov, RH Greiner, GL Semenza: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res, 61(7), 2911-6 (2001)
11. P Stadler, A Becker, HJ Feldmann, G Hansgen, J Dunst, F Wurschmidt, M Molls: Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys, 44(4), 749-54 (1999) (Pubitemid 29284123)
12. K Toustrup, BS Sorensen, J Alsner, J Overgaard: Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol, 22(2), 119-27 (2012)
13. GL Semenza: Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci, 33(4), 207-14 (2012)
14. B Ozanne, CS Richards, F Hendler, D Burns, B Gusterson: Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol, 149(1), 9-14 (1986) (Pubitemid 16013282)
15. S Zhang, J Chen, H Jiang, H Ma, B Yang: Antiepidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. Eur J Clin Pharmacol, 68(5), 561-9 (2012)
16. A Christopoulos, SM Ahn, JD Klein, S Kim: Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head Neck, 33(8), 1220-9 (2011)
17. P O-charoenrat, P Rhys-Evans, SA Eccles: Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer, 92(3), 556-68 (2001) (Pubitemid 32735191)
18. PA Kyzas, IW Cunha, JP Ioannidis: Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res, 11(4), 1434-40 (2005) (Pubitemid 40315223)
19. MG Fury, NY Lee, E Sherman, D Lisa, K Kelly, B Lipson, D Carlson, H Stambuk, S Haque, R Shen, D Kraus, J Shah, DG Pfister: A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer (2012)
20. JK Salama, DJ Haraf, KM Stenson, EA Blair, ME Witt, R Williams, R Kunnavakkam, EE Cohen, T Seiwert, EE Vokes: A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twicedaily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol, 22(10), 2304-9 (2011)
21. MG Fury, A Zahalsky, R Wong, E Venkatraman, E Lis, L Hann, T Aliff, W Gerald, M Fleisher, DG Pfister: A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs, 25(2), 165-72 (2007) (Pubitemid 46020876)
22. JP Machiels, S Henry, S Zanetta, MC Kaminsky, N Michoux, D Rommel, S Schmitz, E Bompas, AF Dillies, S Faivre, A Moxhon, T Duprez, J Guigay: Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol, 28(1), 21-8 (2010)
23. SK Williamson, J Moon, CH Huang, PP Guaglianone, M LeBlanc, GT Wolf, SG Urba: Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol, 28(20), 3330-5 (2010)
24. LA Elferink, VA Resto: Receptor-tyrosine-kinasetargeted therapies for head and neck cancer. J Signal Transduct, 2011, 982879 (2011)
25. CJ Barnes, K Ohshiro, SK Rayala, AK El-Naggar, R Kumar: Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res, 13(14), 4291-9 (2007)
26. RE Friedrich, C Hagel, S Bartel-Friedrich: Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy. Anticancer Res, 30(5), 1641-3 (2010)
27. S Schmitz, MC Kaminsky-Forrett, S Henry, S Zanetta, L Geoffrois, E Bompas, A Moxhon, L Mignion, J Guigay, L Knoops, M Hamoir, JP Machiels: Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol, doi: 10.1093/annonc/mdr574 (2012)
28. E Gherardi, W Birchmeier, C Birchmeier, G Vande Woude: Targeting MET in cancer: rationale and progress. Nat Rev Cancer, 12(2), 89-103 (2012)
29. SJ Rogers, C Box, P Chambers, Y Barbachano, CM Nutting, P Rhys-Evans, P Workman, KJ Harrington, SA Eccles: Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol, 218(1), 122-30 (2009)
30. M Hussain, MR Smith, C Sweeney, PG Corn, A Elfiky, MS Gordon, NB Haas, AL Harzstark, R Kurzrock, P Lara, C Lin, A Sella, EJ Small, AI Spira, UN Vaishampayan, NJ Vogelzang, CM Scheffold, D Ballinger, F Schimmoller, DC Smith,: Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. In: J Clin Oncol, 2011 ASCO Annual Meeting Proceedings, 29(Supplement 15), American Society of Clinical Oncology (2011) abstract nr 4516 (2011)
31. EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SH Ou, BJ Dezube, PA Janne, DB Costa, M Varella-Garcia, WH Kim, TJ Lynch, P Fidias, H Stubbs, JA Engelman, LV Sequist, W Tan, L Gandhi, M Mino-Kenudson, GC Wei, SM Shreeve, MJ Ratain, J Settleman, JG Christensen, DA Haber, K Wilner, R Salgia, GI Shapiro, JW Clark, AJ Iafrate: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363(18), 1693-703 (2010)
32. TY Seiwert, R Jagadeeswaran, L Faoro, V Janamanchi, V Nallasura, M El Dinali, S Yala, R Kanteti, EE Cohen, MW Lingen, L Martin, S Krishnaswamy, A Klein-Szanto, JG Christensen, EE Vokes, R Salgia: The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res, 69(7), 3021-31 (2009)
33. AN Brooks, E Kilgour, PD Smith: Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res, 18(7), 1855-62 (2012)
34. ME Marshall, TK Hinz, SA Kono, KR Singleton, B Bichon, KE Ware, L Marek, BA Frederick, D Raben, LE Heasley: Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res, 17(15), 5016-25 (2011)
35. A Gnoni, I Marech, N Silvestris, A Vacca, V Lorusso: Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets, 12(4), 563-78 (2011)
36. F Stegmeier, M Warmuth, WR Sellers, M Dorsch: Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther, 87(5), 543-52 (2010)
37. B Bran, G Bran, K Hormann, F Riedel: The plateletderived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Int J Oncol, 34(1), 255-61 (2009)
38. EB Pasquale: Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer, 10(3), 165-80 (2010)
39. R Masood, SR Kumar, UK Sinha, DL Crowe, V Krasnoperov, RK Reddy, S Zozulya, J Singh, G Xia, D Broek, AH Schonthal, PS Gill: EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer, 119(6), 1236-48 (2006) (Pubitemid 44258795)
40. RS Rivera, M Gunduz, H Nagatsuka, E Gunduz, B Cengiz, K Fukushima, LB Beder, D Pehlivan, N Yamanaka, K Shimizu, N Nagai: Involvement of EphA2 in head and neck squamous cell carcinoma: mRNA expression, loss of heterozygosity and immunohistochemical studies. Oncol Rep, 19(5), 1079-84 (2008)
41. Z Shao, WF Zhang, XM Chen, ZJ Shang: Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol, 44(12), 1110-7 (2008)
42. Z Wu, JB Doondeea, AM Gholami, MC Janning, S Lemeer, K Kramer, SA Eccles, SM Gollin, R Grenman, A Walch, SM Feller, B Kuster: Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics, 10(12), M111 011635 (2011)
43. R Noberini, I Lamberto, EB Pasquale: Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol, 23(1), 51-7 (2012)
44. R Avraham, Y Yarden: Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol, 12(2), 104-17 (2011)
45. P O-Charoenrat, P Rhys-Evans, S Eccles: Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression. Anticancer Res, 21(3B), 1953-63 (2001) (Pubitemid 32728936)
46. MR Campbell, D Amin, MM Moasser: HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res, 16(5), 1373-83 (2010)
47. KR Legate, E Montanez, O Kudlacek, R Fassler: ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol, 7(1), 20-31 (2006) (Pubitemid 43361569)
48. M Agulnik: New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol, doi: 10.1007/s12032-012-0159-2 (2012)
49. L Vecchione, B Jacobs, N Normanno, F Ciardiello, S Tejpar: EGFR-targeted therapy. Exp Cell Res, 317(19), 2765-71 (2011)
50. W Bergler, H Bier, U Ganzer: The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer. Arch Otorhinolaryngol, 246(3), 121-5 (1989) (Pubitemid 19166320)
51. J Rubin Grandis, MF Melhem, EL Barnes, DJ Tweardy: Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer, 78(6), 1284-92 (1996) (Pubitemid 26303896)
52. CR Leemans, BJ Braakhuis, RH Brakenhoff: The molecular biology of head and neck cancer. Nat Rev Cancer, 11(1), 9-22 (2011)
53. V Ratushny, I Astsaturov, BA Burtness, EA Golemis, JS Silverman: Targeting EGFR resistance networks in head and neck cancer. Cell Signal, 21(8), 1255-68 (2009)
54. NG Chau, B Perez-Ordonez, K Zhang, NA Pham, J Ho, T Zhang, O Ludkovski, L Wang, EX Chen, MS Tsao, S Kamel-Reid, LL Siu: The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol, 3, 11 (2011)
55. K Brunner, CA Fischer, O Driemel, A Hartmann, G Brockhoff, S Schwarz: EGFR (HER) family protein expression and cytogenetics in 219 squamous cell carcinomas of the upper respiratory tract: ERBB2 overexpression independent prediction of poor prognosis. Anal Quant Cytol Histol, 32(2), 78-89 (2010)
56. R Del Sordo, F Angiero, G Bellezza, A Cavaliere, MG Mameli, M Stefani, E Dessy, A Sidoni: HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance. J Oral Pathol Med, 39(1), 79-86 (2010)
57. G Sithanandam, LM Anderson: The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther, 15(7), 413-48 (2008) (Pubitemid 351822188)
58. M Takikita, R Xie, JY Chung, H Cho, K Ylaya, SM Hong, CA Moskaluk, SM Hewitt: Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med, 9, 126 (2011)
59. P O-charoenrat, PH Rhys-Evans, H Modjtahedi, SA Eccles: The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol, 38(7), 627-40 (2002) (Pubitemid 34880101)
60. LF Chen, EE Cohen, Jr. Grandis: New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res, 16(9), 2489-95 (2010)
61. I Barnea, S Haif, R Keshet, V Karaush, S Lev-Ari, A Khafif, A Shtabsky, Y Yarden, A Vexler, RB. Yosef: Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: Results of in vitro and in vivo studies. Head Neck, doi: 10.1002/hed.22967 (2012)
62. JC Peak, NP Jones, S Hobbs, M Katan, SA Eccles: Phospholipase C gamma 1 regulates the Rap GEF1-Rap1 signalling axis in the control of human prostate carcinoma cell adhesion. Oncogene, 27(20), 2823-32 (2008) (Pubitemid 351620454)
63. H Nozawa, G Howell, S Suzuki, Q Zhang, Y Qi, J Klein-Seetharaman, A Wells, JR Grandis,SM Thomas: Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res, 14(13), 4336-44 (2008)
64. SM Thomas, FM Coppelli, A Wells, WE Gooding, J Song, J Kassis, SD Drenning, JR Grandis: Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res, 63(17), 5629- 35 (2003) (Pubitemid 37139888)
65. Q Zhang, SM Thomas, S Xi, TE Smithgall, JM Siegfried, J Kamens, WE Gooding, JR Grandis: SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res, 64(17), 6166-73 (2004) (Pubitemid 39129418)
66. S Xi, Q Zhang, KF Dyer, EC Lerner, TE Smithgall, WE Gooding, J Kamens, JR Grandis: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem, 278(34), 31574-83 (2003)
67. KS Spencer, D Graus-Porta, J Leng, NE Hynes, RL Klemke: ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol, 148(2), 385-97 (2000) (Pubitemid 30078250)
68. C Cripps, E Winquist, MC Devries, D Stys-Norman, R Gilbert: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol, 17(3), 37-48 (2010)
69. NS Dhomen, J Mariadason, N Tebbutt, AMScott: Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog, 17(1), 31-50 (2012)
70. C Fung, JR Grandis: Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs, 15(3), 355-73 (2010)
71. ME Sharafinski, RL Ferris, S Ferrone, JR Grandis: Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck, 32(10), 1412-21 (2010)
72. Y Rukazenkov, G Speake, G Marshall, J Anderton, BR Davies, RW Wilkinson, DM Hickinson, A Swaisland: Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs, 20(10), 856-66 (2009)
73. EE Cohen, MA Kane, MA List, BE Brockstein, B Mehrotra, D Huo, AM Mauer, C Pierce, A Dekker, EE Vokes: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res, 11(23), 8418-24 (2005) (Pubitemid 41746956)
74. DL Wheeler, EF Dunn, PM Harari: Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol, 7(9), 493-507 (2010)
75. A Cassell, JR Grandis: Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs, 19(6), 709-22 (2010)
76. EE Cohen, DW Davis, TG Karrison, TY Seiwert, SJ Wong, S Nattam, MF Kozloff, JI Clark, DH Yan, W Liu, C Pierce, JE Dancey, K Stenson, E Blair, A Dekker, EE Vokes: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol, 10(3), 247-57 (2009)
77. DS Yoo, JP Kirkpatrick, O Craciunescu, G Broadwater, BL Peterson, MD Carroll, R Clough, JR MacFall, J Hoang, RL Scher, RM Esclamado, FR Dunphy, NE Ready, DM Brizel: Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res, 18(5), 1404-14 (2012)
78. N Kondo, M Tsukuda, Y Ishiguro, M Kimura, K Fujita, A Sakakibara, H Takahashi, G Toth, H Matsuda: Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep, 23(4), 957-63 (2010)
79. JM Del Campo, R Hitt, P Sebastian, C Carracedo, D Lokanatha, J Bourhis, S Temam, D Cupissol, D De Raucourt, N Maroudias, CM Nutting, N Compton, D Midwinter, L Downie, N Biswas-Baldwin, I El-Hariry, KJ Harrington: Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer, 105(5), 618-27 (2011)
80. JA de Souza, DW Davis, Y Zhang, A Khattri, TY Seiwert, S Aktolga, S Wong, MF Kozloff, S Nattam, MW Lingen, R Kunnavakkam, KM Stenson, EA Blair, J Bozeman, JE Dancey, EE Vokes, EE Cohen: A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res, 18(8), 2336-43 (2012)
81. D Jackman, W Pao, GJ Riely, JA Engelman, MG Kris, PA Janne, T Lynch, BE Johnson, VA Miller: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol, 28(2), 357-60 (2010)
82. G Giaccone, Y Wang: Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev, 37(6), 456-64 (2011)
83. SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, DW Kim, DH Chung, SA Im, YT Kim, JS Lee, DS Heo, YJ Bang, NK Kim: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol, 23(11), 2493-501 (2005) (Pubitemid 47050839)
84. J Loeffler-Ragg, M Witsch-Baumgartner, A Tzankov, W Hilbe, I Schwentner, GM Sprinzl, G Utermann, H Zwierzina: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer, 42(1), 109-11 (2006) (Pubitemid 41814540)
85. EH Tan, C Goh, WT Lim, KC Soo, ML Khoo, T Tan, DS Tan, MK Ang, QS Ng, PH Tan, A Lim, J Hwang, YH Teng, TH Lim, SH Tan, N Baskaran, KM Hui: Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Ann Oncol, 23(4), 1010-6 (2012)
86. EE Cohen, DJ Haraf, R Kunnavakkam, KM Stenson, EA Blair, B. Brockstein, EP Lester, JK Salama, A Dekker, R Williams, ME Witt, TA Grushko, JJ Dignam, MW Lingen, OI Olopade, EE Vokes: Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol, 28(20), 3336-43 (2010)
87. JS Stewart, EE Cohen, L Licitra, CM Van Herpen, C Khorprasert, D Soulieres, P Vodvarka, D Rischin, AM Garin, FR Hirsch, M Varella-Garcia, S Ghiorghiu, L Hargreaves, A Armour, G Speake, A Swaisland, EE Vokes: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol, 27(11), 1864-71 (2009)
88. S Wheeler, DR Siwak, R Chai, C LaValle, RR Seethala, L Wang, K Cieply, C Sherer, C Joy, GB Mills, A Argiris, JM Siegfried, JR Grandis, AM Egloff: Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res, 18(8), 2278-89 (2012)
89. N Stransky, AM Egloff, AD Tward, AD Kostic, K Cibulskis, A Sivachenko, GV Kryukov, MS Lawrence, C Sougnez, A McKenna, E Shefler, AH Ramos, P Stojanov, SL Carter, D Voet, ML Cortes, D Auclair, MF Berger, G Saksena, C Guiducci, RC Onofrio, M Parkin, M Romkes, JL Weissfeld, RR Seethala, L Wang, C Rangel-Escareno, JC Fernandez- Lopez, A Hidalgo-Miranda, J Melendez-Zajgla, W Winckler, K Ardlie, SB Gabriel, M Meyerson, ES Lander, G Getz, TR Golub, LA Garraway, JR Grandis: The mutational landscape of head and neck squamous cell carcinoma. Science, 333(6046), 1157-60 (2011)
90. LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, P Fidias, K Bergethon, AT Shaw, S Gettinger, AK Cosper, S Akhavanfard, RS Heist, J Temel, JG Christensen, JC Wain, TJ Lynch, K Vernovsky, EJ Mark, M Lanuti, AJ Iafrate, M Mino-Kenudson, JA Engelman: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3(75), 75ra26 (2011)
91. ME Irwin, KL Mueller, N Bohin, Y Ge, JL Boerner: Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol, 226(9), 2316-28 (2011)
92. AJ Mantha, KE McFee, N Niknejad, G Goss, IA Lorimer, J Dimitroulakos: Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol, 129(11), 631-41 (2003) (Pubitemid 37452629)
93. TM Brand, M Iida, C Li, DL Wheeler: The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med, 12(66), 419-32 (2011)
94. WC Huang, YJ Chen, LY Li, YL Wei, SC Hsu, SL Tsai, PC Chiu, WP Huang, YN Wang, CH Chen, WC Chang, AJ Chen, CH Tsai, MC Hung: Nuclear translocation of epidermal growth factor receptor by Aktdependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem, 286(23), 20558-68 (2011)
95. LG Morris, BS Taylor, TG Bivona, Y Gong, S Eng, CW Brennan, A Kaufman, ER Kastenhuber, VE Banuchi, B Singh, A Heguy, A Viale, IK Mellinghoff, J Huse, I Ganly, TA Chan: Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A, 108(47), 19024-9 (2011)
96. N Kondo, M Tsukuda, A Sakakibara, H Takahashi, H Hyakusoku, M Komatsu, T Niho, K Nakazaki, G Toth: Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines. Int J Oncol, 40(6), 1805-12 (2012)
97. K Erjala, M Sundvall, TT Junttila, N Zhang, M Savisalo, P Mali, J Kulmala, J Pulkkinen, R Grenman, K Elenius: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res, 12(13), 4103-11 (2006) (Pubitemid 44078099)
98. B Schoeberl, AC Faber, D Li, MC Liang, K Crosby, M Onsum, O Burenkova, E Pace, Z Walton, L Nie, A Fulgham, Y Song, UB Nielsen, JA Engelman, KK Wong: An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res, 70(6), 2485-94 (2010)
99. JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, N Lindeman, CM Gale, X Zhao, J Christensen, T Kosaka, AJ Holmes, AM Rogers, F Cappuzzo, T Mok, C Lee, BE Johnson, LC Cantley, PA Janne: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316(5827), 1039-43 (2007) (Pubitemid 46799492)
100. M Guix, AC Faber, SE Wang, MG Olivares, Y Song, S Qu, C Rinehart, B Seidel, D Yee, CL Arteaga, JA Engelman: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGFbinding proteins. J Clin Invest, 118(7), 2609-19 (2008) (Pubitemid 351949788)
101. MJ Jameson, AD Beckler, LE Taniguchi, A Allak, LB Vanwagner, NG Lee, WC Thomsen, MA Hubbard, CY Thomas: Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol Cancer Ther, 10(11), 2124-34 (2011)
102. F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, MP Galais, L Bastit, A Killian, R Sesboue, JJ Tuech, AM Queuniet, B Paillot, JC Sabourin, F Michot, P Michel, T Frebourg: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer, 96(8), 1166-9 (2007)
103. A Lievre, JB Bachet, D Le Corre, V Boige, B Landi, JF Emile, JF Cote, G Tomasic, C Penna, M Ducreux, P Rougier, . Penault-Llorca, P Laurent-Puig: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66(8), 3992-5 (2006)
104. DA Eberhard, BE Johnson, LC Amler, AD Goddard, SL Heldens, RS Herbst, WL Ince, PA Janne, T Januario, DH Johnson, P Klein, VA Miller, MA Ostland, DA Ramies, D Sebisanovic, JA Stinson, YR Zhang, S Seshagiri, KJ Hillan: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23(25), 5900-9 (2005)
105. H Linardou, IJ Dahabreh, D Kanaloupiti, F Siannis, D Bafaloukos, P Kosmidis, CA Papadimitriou, S Murray: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol, 9(10), 962-72 (2008)
106. JA Anderson, JC Irish, CM McLachlin, BY Ngan: Hras oncogene mutation and human papillomavirus infection in oral carcinomas. Arch Otolaryngol Head Neck Surg, 120(7), 755-60 (1994) (Pubitemid 24217590)
107. AK Murugan, NT Hong, TT Cuc, NC Hung, AK Munirajan, MA Ikeda, N Tsuchida: Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer. Oral Oncol, 45(10), e161-6 (2009)
108. R Bianco, I Shin, CA Ritter, FM Yakes, A Basso, N Rosen, J Tsurutani, PA Dennis, GB Mills, CL Arteaga: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene, 22(18), 2812-22 (2003) (Pubitemid 36609595)
109. ML Sos, M Koker, BA Weir, S Heynck, R Rabinovsky, T Zander, JM Seeger, J Weiss, F Fischer, P Frommolt, K Michel, M Peifer, C Mermel, L Girard, M Peyton, AF Gazdar, JD Minna, LA Garraway, H Kashkar, W Pao, M Meyerson, RK Thomas: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 69(8), 3256-61 (2009)
110. JT Garrett, CL Arteaga: Resistance to HER2- directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther, 11(9), 793-800 (2011)
111. P Zindy, Y Berge, B Allal, T Filleron, S Pierredon, A Cammas, S Beck, L Mhamdi, L Fan, G Favre, JP Delord, H Roche, F Dalenc, M Lacroix-Triki, S Vagner: Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res, 71(12), 4068-73 (2011)
112. P Timpson, AS Wilson, GM Lehrbach, RL Sutherland, EA Musgrove, RJ Daly: Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res, 67(19), 9304-14 (2007) (Pubitemid 47535919)
113. Y Haddad, W Choi, DJ McConkey: Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res, 15(2), 532-42 (2009)
114. S Maseki, K Ijichi, H Tanaka, M Fujii, Y Hasegawa, T Ogawa, S Murakami, E Kondo, H Nakanishi: Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br J Cancer, 106(6), 1196-204 (2012)
115. A Jain, CA Tindell, I Laux, JB Hunter, J Curran, A Galkin, DE Afar, N Aronson, S Shak, RB Natale, DB Agus: Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A, 102(33), 11858-63 (2005)
116. LJ Kornberg, D Villaret, M Popp, L Lui, R McLaren, H Brown, D Cohen, J Yun, M McFadden: Gene expression profiling in squamous cell carcinoma of the oral cavity shows abnormalities in several signaling pathways. Laryngoscope, 115(4), 690-8 (2005) (Pubitemid 40530023)
117. P Workman, PA Clarke: Resisting targeted therapy: fifty ways to leave your EGFR. Cancer Cell, 19(4), 437-40 (2011)
118. HC Thoeny, BD Ross: Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging, 32(1), 2-16 (2010)
119. LA Byers, FC Holsinger, MS Kies, WN William, AK El-Naggar, JJ Lee, J Hu, A Lopez, HT Tran, S Yan, Z Du, KK Ang, BS Glisson, MG Raso, II Wistuba, JN Myers, WK Hong, V Papadimitrakopoulou, SM Lippman, JV Heymach: Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther, 9(6), 1755-63 (2010)
120. SH Ou: Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol, Epub ahead of print doi: 10.1016/j.critrevonc.2011.11.010 (2012)
121. KM Quesnelle, JR Grandis: Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance. Clin Cancer Res, 17(18), 5935-44 (2011)
122. V Hirsh: Afatinib (BIBW 2992) development in nonsmall- cell lung cancer. Future Oncol, 7(7), 817-25 (2011)
123. VA Miller, V Hirsh, J Cadranel, YM Chen, K Park, SW Kim, C Zhou, WC Su, M Wang, Y Sun, DS Heo, L Crino, EH Tan, TY Chao, M Shahidi, XJ Cong, RM Lorence, JC Yang: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 13(5), 528-38 (2012)
124. LL Siu, SJ Hotte, SA Laurie, S Singh, E Winquist, SKL Chia, EX Chen, KK Chan, T Wang, I Taylor, A Ruiz- Garcia, C Mormont, D Soulieres: Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). In: J Clin Oncol, 2011 ASCO Annual Meeting Proceedings, 29(Supplement 15), American Society of Clinical Oncology abstract nr 5561 (2011)
125. DW Fry: Site-directed irreversible inhibitors of the erbB family of
126. Y Pan, Y Xu, S Feng, S Luo, R Zheng, J Yang, L Wang, L Zhong, HY Yang, BL Wang, Y Yu, J Liu, Z Cao, X Wang, P Ji, Z Wang, X Chen, S Zhang, YQ Wei, SY Yang: SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo. Mol Cancer Ther, 11(4), 952-62 (2012)
127. MC Pietanza, TJ Lynch, Jr., PN Lara, Jr., J Cho, RH Yanagihara, N Vrindavanam, NM Chowhan, SM Gadgeel, NA Pennell, R Funke, B Mitchell, HA Wakelee, VA Miller: XL647-a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol, 7(1), 219-26 (2012)
128. J Chmielecki, MC Pietanza, D Aftab, R Shen, Z Zhao, X Chen, K Hutchinson, A Viale, MG Kris, T Stout, V Miller, N Rizvi, W Pao: EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. J Thorac Oncol, 7(2), 434-42 (2012)
129. OG Yigitbasi, MN Younes, D Doan, SA Jasser, BA Schiff, CD Bucana, BN Bekele, IJ Fidler, JN Myers: Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res, 64(21), 7977-84 (2004) (Pubitemid 39446932)
130. JD Klein, A Christopoulos, SM Ahn, WE Gooding, JR Grandis, S Kim: Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head Neck, Epub ahead of print doi: 10.1002/hed.21917 (2012)
131. D Sano, F Matsumoto, DR Valdecanas, M Zhao, DP Molkentine, Y Takahashi, EY Hanna, V Papadimitrakopoulou, J Heymach, L Milas, JN Myers: Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res, 17(7), 1815-27 (2011)
132. P Workman, F Burrows, L Neckers, N Rosen: Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci, 1113, 202-16 (2007) (Pubitemid 350015011)
133. CC Chiu, CY Lin, LY Lee, YJ Chen, YC Lu, HM Wang, CT Liao, JT Chang, AJ Cheng: Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer. Clin Cancer Res, 17(14), 4629-41 (2011)
134. S Sanderson, M Valenti, S Gowan, L Patterson, Z Ahmad, P Workman, SA Eccles: Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther, 5(3), 522-32 (2006)
135. SA Eccles, A Massey, FI Raynaud, SY Sharp, G Box, M Valenti, L Patterson, A de Haven Brandon, S Gowan, F Boxall, W Aherne, M Rowlands, A Hayes, V Martins, F Urban, K Boxall, C Prodromou, L Pearl, K James, TP Matthews, KM Cheung, A Kalusa, K Jones, E McDonald, X Barril, PA Brough, JE Cansfield, B Dymock, MJ Drysdale, H Finch, R Howes, RE Hubbard, A Surgenor, P Webb, M Wood, L Wright, P Workman: NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res, 68(8), 2850-60 (2008) (Pubitemid 351556284)
136. S Zaidi, M McLaughlin, SA Bhide, SA Eccles, P Workman, CM Nutting, RA Huddart, KJ Harrington: The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One, 7(4), e35436 (2012)
137. P Kabolizadeh, GJ Kubicek, DE Heron, RL Ferris, MK Gibson: The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther, 12(4), 517- 28 (2012)
138. C Moon, YK Chae, J Lee: Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood), 235(8), 907-20 (2010)
139. H Kimura, K Sakai, T Arao, T Shimoyama, T Tamura, K Nishio: Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci, 98(8), 1275- 80 (2007) (Pubitemid 46993549)
140. P Specenier, JB Vermorken: Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther, 11(4), 511-24 (2011)
141. R Mehra, IG Serebriiskii, RL Dunbrack, Jr., MK Robinson, B. Burtness, EA Golemis: Protein-intrinsic and signaling network-based sources of resistance to EGFRand ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat, 14(6), 260-79 (2011)
142. JA Bonner, PM Harari, J Giralt, N Azarnia, DM Shin, RB Cohen, CU Jones, R Sur, D Raben, J Jassem, R Ove, MS Kies, J Baselga, H Youssoufian, N Amellal, EK Rowinsky, KK Ang: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354(6), 567-78 (2006) (Pubitemid 43209104)
143. F Rivera, A Garcia-Castano, N Vega, ME Vega- Villegas, L Gutierrez-Sanz: Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther, 9(10), 1421-8 (2009)
144. DA de Andrade, JP Machiels: Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. Curr Opin Oncol, 24(3), 211-7 (2012)
145. JP Machiels, S Subramanian, A Ruzsa, G Repassy, I Lifirenko, A Flygare, P Sorensen, T Nielsen, S Lisby, PM Clement: Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an openlabel, randomised phase 3 trial. Lancet Oncol, 12(4), 333- 43 (2011)
146. U Schick, DM Gujral, TM Richards, KJ Harrington, CM Nutting: Zalutumumab in head and neck cancer. Expert Opin Biol Ther, 12(1), 119-25 (2012)
147. C Berger, U Krengel, E Stang, E Moreno, IH Madshus: Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. J Immunother, 34(7), 550-5 (2011)
148. C Basavaraj, P Sierra, J Shivu, R Melarkode, E Montero, P Nair: Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol Ther, 10(7), 673-81 (2010)
149. B Kuenen, PO Witteveen, R Ruijter, G Giaccone, A Dontabhaktuni, F Fox, T Katz, H Youssoufian, J Zhu, EK Rowinsky, EE Voest: A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res, 16(6), 1915-23 (2010)
150. A Argiris, AG Duffy, S Kummar, NL Simone, Y Arai, SW Kim, SF Rudy, VR Kannabiran, X Yang, M Jang, Z Chen, N Suksta, T Cooley-Zgela, SG Ramanand, A Ahsan, MK Nyati, JJ Wright, C Van Waes: Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res, 17(17), 5755-64 (2011)
151. R Croasdale, K Wartha, JM Schanzer, KP Kuenkele, C Ries, K Mayer, C Gassner, M Wagner, N Dimoudis, S Herter, C Jaeger, C Ferrara, E Hoffmann, L Kling, W Lau, RF Staack, J Heinrich, W Scheuer, J Stracke, C Gerdes, U Brinkmann, P Umana, C Klein: Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys, Epub ahead of print doi: 10.1016/j.abb.2012.03.016 (2012)
152. D Lu, H Zhang, H Koo, J Tonra, P Balderes, M Prewett, E Corcoran, V Mangalampalli, R Bassi, D Anselma, D Patel, X Kang, DL Ludwig, DJ Hicklin, P Bohlen, L Witte, Z Zhu: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem, 280(20), 19665-72 (2005)
153. AV Kamath, D Lu, P Gupta, D Jin, H. Xiang, A Wong, C Leddy, L Crocker, G Schaefer, MX Sliwkowski, LA Damico- Beyer: Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol, 69(4), 1063-9 (2012)
154. SJ Hurwitz, H Zhang, S Yun, TD Batuwangala, M Steward, SD Holmes, D Rycroft, L Pan, M Tighiouart, HJ Shin, L Koenig, Y Wang, ZG. Chen, DM Shin: Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice. Cancer Chemother Pharmacol, 69(3), 577-90 (2012)
155. RC Roovers, MJ Vosjan, T Laeremans, R El Khoulati, RC de Bruin, KM Ferguson, AJ Verkleij, GA van Dongen, PM van Bergen En Henegouwen: A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer, 129(8), 2013-2024 (2011)
156. Z Liu, Y Liu, B Jia, H Zhao, X Jin, F Li, X Chen, F Wang: Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther, 9(8), 2297-308 (2010)
157. M Harris, XG Wang, Z Jiang, GL Goldberg, A Casadevall, E Dadachova: Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol, 3(1), 9 (2011)
158. A. Sartore-Bianchi, M Moroni, S Veronese, C Carnaghi, E Bajetta, G Luppi, A Sobrero, C. Barone, S Cascinu, G Colucci, E Cortesi, M Nichelatti, M Gambacorta, S Siena: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol, 25(22), 3238-45 (2007) (Pubitemid 47325607)
159. L Licitra, R Mesia, F Rivera, E Remenar, R Hitt, J Erfan, S Rottey, A Kawecki, D Zabolotnyy, M Benasso, S Storkel, S Senger, C Stroh, JB Vermorken: Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol, 22(5), 1078-87 (2011)
160. JC Sok, FM Coppelli, SM Thomas, MN Lango, S Xi, JL Hunt, ML Freilino, MW Graner, CJ Wikstrand, DD Bigner, WE Gooding, FB Furnari, JR Grandis: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res, 12(17), 5064-73 (2006) (Pubitemid 44453332)
161. C Montagut, A Dalmases, B Bellosillo, M Crespo, S Pairet, M Iglesias, M Salido, M Gallen, S Marsters, SP Tsai, A Minoche, S Somasekar, S Serrano, H Himmelbauer, J Bellmunt, A Rovira, J Settleman, F Bosch, J Albanell: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med, 18(2), 221-3 (2012)
162. I Tinhofer, K Klinghammer, W Weichert, M Knodler, A Stenzinger, T Gauler, V Budach, U Keilholz: Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res, 17(15), 5197-204 (2011)
163. H Hatakeyama, H Cheng, P Wirth, A Counsell, SR Marcrom, CB Wood, PR Pohlmann, JGilbert, B Murphy, WG Yarbrough, DL Wheeler, PM Harari, Y Guo, Y Shyr, RJ Slebos, CH Chung: Regulation of heparin-binding EGFlike growth factor by miR-212 and acquired cetuximabresistance in head and neck squamous cell carcinoma. PLoS One, 5(9), e12702 (2010)
164. DL Wheeler, M Iida, TJ Kruser, MM Nechrebecki, EF Dunn, EA Armstrong, S Huang, PM Harari: Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther, 8(8), 696-703 (2009)
165. C Li, M Iida, EF Dunn, AJ Ghia, DL Wheeler: Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene, 28(43), 3801-13 (2009)
166. R Krumbach, J Schuler, M Hofmann, T Giesemann, HH Fiebig, T Beckers: Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer, 47(8), 1231-43 (2011)
167. K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, D Ercan, A Rogers, M Roncalli, M Takeda, Y Fujisaka, J Philips, T Shimizu, O Maenishi, Y Cho, J Sun, A Destro, K Taira, K Takeda, T Okabe, J Swanson, H Itoh, M Takada, E Lifshits, K Okuno, JA Engelman, RA Shivdasani, K Nishio, M Fukuoka, M Varella-Garcia, K Nakagawa, PA Janne: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med, 3(99), 99ra86 (2011)
168. DH Shin, HY Min, AK El-Naggar, SM Lippman, B Glisson, HY Lee: Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther, 10(12), 2437-48 (2011)
169. A Viloria-Petit, T Crombet, S Jothy, D Hicklin, P Bohlen, JM Schlaeppi, J Rak, RS Kerbel: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res, 61(13), 5090-101 (2001) (Pubitemid 32681540)
170. A Argiris, SC Lee, T Feinstein, S Thomas, BF Branstetter, R Seethala, L Wang, W Gooding, JR Grandis, RL Ferris: Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol, 47(10), 961-6 (2011)
171. HD Brooks, BS Glisson, BN Bekele, LE Ginsberg, A El-Naggar, KS Culotta, N Takebe, J Wright, HT Tran, VA Papadimitrakopoulou: Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer, 117(10), 2112-9 (2011)
172. G Martiny-Baron, P Holzer, E Billy, C Schnell, J Brueggen, M Ferretti, N Schmiedeberg, JM Wood, P Furet, P Imbach: The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis, 13(3), 259-67 (2010)
173. K Freier, C Schwaenen, C Sticht, C Flechtenmacher, J Muhling, C Hofele, B Radlwimmer, P Lichter, S Joos: Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol, 43(1), 60-6 (2007) (Pubitemid 46162249)
174. Y Zhang, Y Hiraishi, H Wang, KS Sumi, Y Hayashido, S Toratani, M Kan, JD Sato, T Okamoto: Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer, 117(1), 166-8 (2005) (Pubitemid 41262771)
175. DT Rieke, Z Zuo, K Endhardt, M Keck, A Khattri, D Mahmutogulu, K Leung, M El Dinali, J Braegelmann, TY Seiwert,: Fibroblast growth factors in head and neck cancer: Genetic alterations and therapeutic targeting with ponatinib. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 2012 March 31-April 4; Chicago, Illinois. Washington,DC. Philadelphia: AACR p 7 abstract nr 2832 (2012)
176. M Resnicoff, JL Burgaud, HL Rotman, D Abraham, R Baserga: Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res, 55(17), 3739-41 (1995)
177. R Baserga: The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets, 9(4), 753- 68 (2005) (Pubitemid 41131677)
178. LM Knowles, LP Stabile, AM Egloff, ME Rothstein, SM Thomas, CT Gubish, EC Lerner, RR Seethala, S Suzuki, KM Quesnelle, S Morgan, RL Ferris, JR Grandis, JM Siegfried: HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res, 15(11), 3740-50 (2009)
179. JD Schultz, S Rotunno, F Riedel, C Anders, P Erben, RD Hofheinz, A Faber, C Thorn, JU Sommer, K Hormann, A Sauter: Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Ralpha/ss expression in squamous cell carcinoma of the head and neck in vitro. Int J Oncol, 38(4), 1001-12 (2011)
180. TJ Kruser, DL Wheeler, EA Armstrong, M Iida, KR Kozak, AJ van der Kogel, J Bussink, A Coxon, A Polverino, PM Harari: Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res, 16(14), 3639-47 (2010)
181. MM Cooney, KY Tserng, V Makar, RJ McPeak, ST Ingalls, A Dowlati, B Overmoyer, K McCrae, P Ksenich, P Lavertu, P Ivy, CL Hoppel, S Remick: A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol, 55(3), 295-300 (2005) (Pubitemid 40142895)
182. C Elser, LL Siu, E Winquist, M Agulnik, GR Pond, SF Chin, P Francis, R Cheiken, J Elting, A McNabola, D Wilkie, O Petrenciuc, EX Chen: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol, 25(24), 3766-73 (2007) (Pubitemid 47372619)
183. G Fountzilas, A Fragkoulidi, A Kalogera-Fountzila, M Nikolaidou, M Bobos, J Calderaro, F Andreiuolo, M Marselos: A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol, 65(4), 649-60 (2010)
184. NW Choong, M Kozloff, D Taber, HS Hu, J Wade, 3rd, P Ivy, TG Karrison, A Dekker, EE Vokes, EE Cohen: Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs, 28(5), 677-83 (2010)
185. D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 22(1), 77-85 (2004) (Pubitemid 41095117)
186. LL Siu, D Soulieres, EX Chen, GR Pond, SF Chin, P Francis, L Harvey, M Klein, W Zhang, J Dancey, EA Eisenhauer, E Winquist: Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol, 25(16), 2178-83 (2007) (Pubitemid 46954640)
187. A Argiris, M Ghebremichael, J Gilbert, B Burtness, A Forastiere: A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). In: J Clin Oncol, 2009 ASCO Annual Meeting Proceedings, 27(Supplement 15), American Society of Clinical Oncology abstract nr 6011 (2009)
188. H Xu, LP Stabile, CT Gubish, WE Gooding, JR Grandis, JM Siegfried: Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res, 17(13), 4425-38 (2011)
189. F Bruzzese, A Leone, M Rocco, C Carbone, G Piro, M Caraglia, E Di Gennaro, A Budillon: HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol, 226(9), 2378-90 (2011)
190. V Papadimitrakopoulou, SJ Frank, GR Blumenschein, C Chen, M Kane, EE Cohen, P Langmuir, AD Krebs, SM Lipmann, D Raben: Phase I evaluation of vandetanib with radiation therapy (RT) +/- cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). In: J Clin Oncol, 2009 ASCO Annual Meeting Proceedings, 29(Supplement 15), American Society of Clinical Oncology abstract nr 6016 (2009)
191. T Seiwert, PM Clement, D Cupissol, J Del Campo, H de Mont-Serrat, GC Thurm, AS Blackman, EE Cohen: BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinumcontaining therapy with a cross-over period for processing patients: Preliminary results of a randomized, open-label phase II study. In: J Clin Oncol, 2010 ASCO Annual Meeting Proceedings, 27(Supplement 15), American Society of Clinical Oncology abstract nr 5501 (2010)
192. JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, T Shimamura, F Zhao, PW Vincent, GN Naumov, JE Bradner, IW Althaus, L Gandhi, GI Shapiro, JM Nelson, JV Heymach, M Meyerson, KK Wong, PA Janne: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res, 67(24), 11924-32 (2007)
193. F Tan, X Shen, D Wang, G Xie, X Zhang, L Ding, Y Hu, W He, Y Wang: Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 76(2), 177-82 (2012)
194. SK Rabindran, CM Discafani, EC Rosfjord, M Baxter, MB Floyd, J Golas, WA Hallett, BD Johnson, R Nilakantan, E Overbeek, MF Reich, R Shen, X Shi, HR Tsou, YF Wang, A Wissner: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res, 64(11), 3958-65 (2004) (Pubitemid 38697310)
195. X Cai, HX Zhai, J Wang, J Forrester, H Qu, L Yin, CJ Lai, R Bao, C Qian: Discovery of 7-(4-(3- ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)- Nhydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem, 53(5), 2000-9 (2010)
196. CJ Lai, R Bao, X Tao, J Wang, R Atoyan, H Qu, DG Wang, L Yin, M Samson, J Forrester, B Zifcak, GX Xu, S DellaRocca, HX Zhai, X Cai, WE Munger, M Keegan, CV Pepicelli, C Qian: CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res, 70(9), 3647-56 (2010)
197. T Shimizu, AW Tolcher, K Papadopoulos, A Patnaik, P LoRusso, LS Smith, M Beeram, D Rasco, G Chambers, M Keegan: The First-in-human, first-in-class study of CUDC- 101, a multi-targeted inhibitor of HDAC, EGFR and HER2: A phase I study in patients with advanced cancer. In: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2010 November 16-19; Berlin, Germany; European CanCer Organisation abstract nr 364 (2010)
198. TW Wong, FY Lee, S Emanuel, C Fairchild, Fargnoli, B Fink, A Gavai, A Hammell, B Henley, C Hilt, JT Hunt, B Krishnan, D Kukral, A Lewin, H Malone, D Norris, S Oppenheimer, G Vite, C Yu: Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. Clin Cancer Res, 17(12), 4031-41 (2011)
199. JB Vermorken, J Trigo, R Hitt, P Koralewski, E Diaz- Rubio, F Rolland, R Knecht, N Amellal, A Schueler, J Baselga: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol, 25(16), 2171-7 (2007)
200. JA Bonner, PM Harari, J Giralt, RB Cohen, CU Jones, RK Sur, D Raben, J Baselga, SA Spencer, J Zhu, H Youssoufian, EK Rowinsky, K K. Ang: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol, 11(1), 21-8 (2010)
201. B Burtness, MA Goldwasser, W Flood, B Mattar, AA Forastiere: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol, 23(34), 8646-54 (2005) (Pubitemid 46211507)
202. JB Vermorken, R Mesia, F Rivera, E Remenar, A Kawecki, S Rottey, J Erfan, D Zabolotnyy, HR Kienzer, D Cupissol, F Peyrade, M Benasso, I Vynnychenko, D De Raucourt, C Bokemeyer, A Schueler, N Amellal, R Hitt: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 359(11), 1116-27 (2008)
203. M Merlano, E Russi, M Benasso, R Corvo, I Colantonio, R Vigna-Taglianti, V Vigo, A Bacigalupo, G Numico, N Crosetto, M Gasco, C Lo Nigro, R Vitiello, S Violante, O Garrone: Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol, 22(3), 712-7 (2011)
204. KK Ang, Q Zhang, DI Rosenthal, PF Nguyen-Tân, E Sherman, R Weber, J Galvin, D Schwartz, A El-Naggar, ML Gillison, R Jordan, M List, A Konski, W Thorstad, JJ Beitler, A Garden, WJ Spanos, A Trotti, SS Yom, R Axelrod: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). In: J Clin Oncol, 2011 ASCO Annual Meeting Proceedings, 29(Supplement 15), American Society of Clinical Oncology abstract nr 5500 (2011)
205. MK Gibson, M Kies, S Kim, P Savvides, A Kotsakis, G Blumenschein, F Worden, H Chen, J Grandis, A Argiris: Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report. In: J Clin Oncol, 2009 ASCO Annual Meeting Proceedings, 27(Supplement 15), American Society of Clinical Oncology abstract nr 6049 (2009)
206. JB Vermorken, J Guigay, R Mesia, JM Trigo, U Keilholz, A Kerber, U Bethe, M Picard, TH Brummendorf: Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer, 104(11), 1691-6 (2011)
207. NE Bhola, SM Thomas, M Freilino, S Joyce, A Sahu, J Maxwell, A Argiris, R Seethala, JR Grandis: Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clin Cancer Res, 17(15), 4996-5004 (2011)
208. A Hoellein, A Pickhard, F von Keitz, S Schoeffmann, G Piontek, M Rudelius, A Baumgart, S Wagenpfeil, C Peschel, T Dechow, H Bier, U Keller: Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget, 2(8), 599-609 (2011)
209. U Vanhoefer, M Tewes, F Rojo, O Dirsch, N Schleucher, O Rosen, J Tillner, A Kovar, AH Braun, T Trarbach, S Seeber, A Harstrick, J Baselga: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol, 22(1), 175-84 (2004) (Pubitemid 41095130)
210. R Dienstmann, E Felip: Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther, 11(9), 1223-31 (2011)
211. MO Rodriguez, TC Rivero, R del Castillo Bahi, CR Muchuli, MA Bilbao, EN Vinageras, J Alert, JJ Galainena, E Rodriguez, E Gracias, B Mulen, B Wilkinson, EL de Armas, K Perez, I Pineda, M Frometa, I Leonard, V Mullens, C Viada, P Luaces, O Torres, N Iznaga, T Crombet: Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther, 9(5), 343-9 (2010)
212. JB Vermorken, J Stohlmacher, I Davidenko, E Winquist, L Licitra, VR Pai, K Skladowski, CR Blajman, S Faivre, J Gansert: An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM). In: J Clin Oncol, 2009 ASCO Annual Meeting Proceedings, 29(Supplement 15), American Society of Clinical Oncology abstract nr 6050 (2009)
213. H Zhang, S Yun, TD Batuwangala, M Steward, SD Holmes, L Pan, M Tighiouart, HJ Shin, L Koenig, W Park, D Rycroft, S Nannapaneni, Y Wang, ZG Chen, DM Shin: A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Int J Cancer, 131(4), 956-969 (2012)
214. G Schaefer, L Haber, LM Crocker, S Shia, L Shao, D Dowbenko, K Totpal, A Wong, CV Lee, S Stawicki, R Clark, C Fields, GD L Phillips, RA Prell, DM Danilenko, Y Franke, JP Stephan, J Hwang, Y Wu, J Bostrom, MX Sliwkowski, G Fuh,C Eigenbrot: A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell, 20(4), 472-86 (2011)